Shots:

• Nuformix is eligible to receive an up front- development milestone along with royalties when the net sales reaching $2.76M/annum
• Oxilio gets an exclusive license to research- develop and commercialize NXP001 globally for oncology indications. The agreement allows Oxilio to focus on developing a unique formulation and dosage form with NXP001 to progress into the clinic
• NXP001 is a new form of aprepitant which is marketed in the oncology supportive care setting. Additionally- Nuformix has obtained the patents on new forms of NXP001 with improved properties & focuses to develop two lead assets NXP002 and NXP004

  | Ref: Nuformix | Image: Linkedin